Stockscreener 앱 받기
9.20
2.56%
0.23
시간 외 거래:
9.20
전일 마감가:
$8.97
열려 있는:
$8.91
하루 거래량:
583.53K
Relative Volume:
0.71
시가총액:
$601.55M
수익:
$89.40M
순이익/손실:
$-221.30M
주가수익비율:
-2.8252
EPS:
-3.2564
순현금흐름:
$-256.90M
1주 성능:
+2.34%
1개월 성능:
+14.86%
6개월 성능:
-19.58%
1년 성능:
+29.76%
1일 변동 폭
$8.894
$9.26
1주일 범위
$8.71
$9.26
52주 변동 폭
$6.955
$14.51
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
9.20 | 586.51M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-10-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-09-24 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-06-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-02 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-03-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
D. E. Shaw adjusts Arvinas (ARVN) stake as one entity falls below 5% - Stock Titan
Arvinas (ARVN) Q2 2026 Earnings Call Transcript - AOL.com
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Enterprise value to EBITDA forward of Arvinas, Inc. – NASDAQ:ARVN - TradingView
ARVN Maintains by Evercore ISI Group -- Price Target Lowered to $14.00 - GuruFocus
ARVN Maintained by Citigroup -- Price Target Lowered to $21.00 - GuruFocus
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $10 - moomoo.com
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $10 to $21 - Moomoo
Arvinas, Inc. Stock 12‑Month Price Target Cut to $13.93, Implies 59% Upside - TradingView
Precision Trading with Arvinas Inc. (ARVN) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BofA Securities Maintains Arvinas(ARVN.US) With Hold Rating - Moomoo
Arvinas (NASDAQ:ARVN) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Arvinas, Inc. (ARVN) stock price, news, quote and history - Yahoo Finance Australia
HC Wainwright Has Pessimistic Outlook of Arvinas Q3 Earnings - MarketBeat
Arvinas Inc (ARVN) Stock News Today - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Bruker (BRKR), Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Arvinas Holding Earnings Call: PROTAC Milestone and Outlook - The Globe and Mail
Transcript: Arvinas Q2 2026 Earnings Conference Call - Sahm
Arvinas (NASDAQ:ARVN) Trading Down 7.8% on Analyst Downgrade - MarketBeat
ARVN Maintains Neutral Rating by Wedbush -- Price Target Raised to $12 - GuruFocus
Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit - TradingKey
BTIG reiterates Arvinas stock Buy rating on pipeline execution By Investing.com - Investing.com UK
Arvinas, Inc. Stock 12‑Month Price Target Cut to $14.85, Implies 84% Upside - TradingView
Arvinas, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ARVN Reiterated by BTIG -- Price Target Maintained at $18.00 - GuruFocus
Arvinas (NASDAQ: ARVN) posts $169.4M profit on VEPPANU and Rigel deals - Stock Titan
ARVINAS, INC. 2026: Revenue $249.7M, EPS $2.58— 10-Q Summary - TradingView
BTIG reiterates Arvinas stock Buy rating on pipeline execution - Investing.com
BTIG Research Reiterates Buy Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Arvinas' (ARVN) "Equal Weight" Rating Reaffirmed at Wells Fargo & Company - marketbeat.com
Earnings call transcript: Arvinas Q2 2026 profit beat lifts outlook - Investing.com
Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating - finance.yahoo.com
Arvinas (NASDAQ:ARVN) Trading 14.8% Higher Following Better-Than-Expected Earnings - MarketBeat
Arvinas Q2 Earnings Call Highlights - MarketBeat
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $2.95 EPS - MarketBeat
Arvinas Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
ARVINAS ($ARVN) Releases Q2 2026 Earnings - Quiver Quantitative
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Arvinas reports $249.7M Q2 revenue, $169.4M net income and guidance into H2 2028 - TradingView
Arvinas Q2 2026 Earnings Call Transcript - MarketBeat
ARVN: FDA approval, major out-licensing, and pipeline focus drive strong Q2 results and outlook - TradingView
Earnings To Watch: Arvinas Inc (ARVN) Q2 2026 -- GF Value Sees 34% Upside - Yahoo Finance
Arvinas (ARVN) Projected to Announce Quarterly Earnings on Wednesday - marketbeat.com
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 - The Manila Times
Arvinas to give corporate update during Aug. 4 webcast - Stock Titan
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
1.77%
자본화:
|
볼륨(24시간):